Aurobindo Pharma’s subsidiary Eugia Pharma Specialities will manufacture and market cancer drug Lenalidomide Capsules. | Photo Credit: The Hindu Drugmaker Aurobindo Pharma’s subsidiary Eugia Pharma Specialities has received final approval from the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market cancer drug Lenalidomide Capsules, in different strengths. The approved product is bioequivalent […]
Continue Reading
Total revenue from operations at ₹5,739.3 crore (₹5,941.9 crore) was 3.4% lower during the quarter Total revenue from operations at ₹5,739.3 crore (₹5,941.9 crore) was 3.4% lower during the quarter Drugmaker Aurobindo Pharma’s consolidated net profit declined more than 41% for the September quarter to ₹410.3 crore on the back of lower revenue from formulations […]
Continue Reading
Aurobindo Pharma Limited senior vice-president (corporate-HR) U.N.B. Raju on Thursday said that the company was according a top priority to providing jobs to the local residents after providing them skill-oriented training. He presented certificates to 25 youth who have successfully completed a four-month training programme jointly organised by Dr. B.R. Ambedkar University and the Aurobindo […]
Continue Reading
Drugmaker Aurobindo Pharma reported first-quarter consolidated net profit slid more than 32% to ₹520.3 crore. The net profit declined on an almost 9% increase in net sales to ₹6,176.8 crore (₹5,691.8 crore). Total income at ₹6,276.5 crore (₹5,811.8 crore) was almost 8% higher. The EBITDA margin stood at 15.5% as against 21.2% in the same […]
Continue Reading
Firm disclosed “very limited and restricted information” to stock exchanges about an U.S. FDA plant audit Firm disclosed “very limited and restricted information” to stock exchanges about an U.S. FDA plant audit The Securities and Exchange Board of India (SEBI) has issued a warning letter to Aurobindo Pharma for disclosing “very limited and restricted information” […]
Continue ReadingCopyright © 2022
Designed and Developed by Cpool Digital Learning
